Martin Shkreli denies allegations he ripped off millions of dollars from Retrophin to repay defrauded investors in his hedge funds. » Read More
By: Dan Mangan
Shkreli denies allegations he ripped off Retrophin out of millions of dollars to repay defrauded investors in his hedge funds. » Read More
Martin Shkreli has blatantly defied his attorneys' advice to lay low. » Read More
Bill Doyle, executive chairman of Novocure, weighs in on the health-care developments in Washington. » Read More
The investigations over the Philidor unit just add to Valeant's struggles to fix its broken business model, says Livermore Partners' David Neuhauser.
CNBC's Meg Tirrell reports the latest details on Valeant and its potential criminal probe. The "Fast Money Halftime Report" traders and Yana Barton, Eaton Vance portfolio manager, add perspective.
Valeant Pharmaceuticals shares fell more than 9 percent in pre-market trading after The Wall Street Journal reported the company is under federal investigation.
John Crowley, Amicus Therapeutics CEO, discusses the development of "orphan drugs" for patients with rare diseases. What I know personally and professionally is if we make great medicines, we'll not only change people lives, we'll build great businesses, says Crowley.
CNBC's Meg Tirrell takes a look at the difficult market for drugs that treat rare diseases.
Valeant Pharmaceuticals fortunes were discussed at a private shareholder dinner attended by top investor and board member William Ackman.
CNBC's Meg Tirrell reports on comments from Valeant CEO Joe Papa following the company's earnings release.
Congress should reconvene, work together across the aisle and push through a funding package compromise now, says Dr. Judith Monroe.
Valeant Pharmaceuticals reported quarterly earnings and revenue that fell short of analysts' expectations on Tuesday.
Jim Cramer suggests investors read JPMorgan's report before they decide to sell Allergan stock.
Allergan reported a bigger second-quarter loss as its Alzheimer's drug, Namenda IR, lost patent exclusivity.
$21 billion is how much investors wiped off the firm after its trial to broaden the use of one of its most promising drugs failed.
Shares of Bristol-Myers Squibb drop on a failed drug trial. Damien Conover, Morningstar equity analyst, discusses his views on the future Bristol-Myers.
Shares of Bristol Myers Squibb are way down today while shares of Merck are up. Here's why, and what's next, with Tony Butler, Guggenheim Securities.
Critical Zika funding legislation is one step (and about four Senate votes) away from the president's desk, says Martha Roby. We need to pass it now.
While Bristol Myers Squibb is having its worst day in nearly 16 years, shares of Merck is up 5 percent year over year. Nancy Tengler, Heartland Financial, discusses one of her largest holdings.
Bristol Myers Squibb is having its worst day in nearly 16 years after failing to meet goals for a lung cancer drug. Alex Arfaei, BMO, discusses.
Jim Cramer said that he was shocked after Bristol-Myers Squibb announced its lung cancer drug failed in a late-stage study.
As Donald Trump dives in the polls, Strategas Research Partners analyzed the investor implications of a potential Democratic sweep in November.
The pharmaceutical company reported its cancer drug failed to reach its goals for treating advanced non-small cell lung cancer.
Get the best of CNBC in your inbox